Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
Saved in:
| Title: | Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. |
|---|---|
| Authors: | Hong DS; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Butler MO; Princess Margaret Hospital Cancer Centre, University of Toronto, Toronto, ON, Canada., Pachynski RK; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States., Sullivan R; Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Kebriaei P; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Boross-Harmer S; Princess Margaret Hospital Cancer Centre, University of Toronto, Toronto, ON, Canada., Ghobadi A; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States., Frigault MJ; Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Dumbrava EE; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Sauer A; Adaptimmune LLC, Philadelphia, PA, United States., Brophy F; Adaptimmune LLC, Philadelphia, PA, United States., Navenot JM; Adaptimmune LLC, Philadelphia, PA, United States., Fayngerts S; Adaptimmune LLC, Philadelphia, PA, United States., Wolchinsky Z; Adaptimmune Limited, Abingdon, United Kingdom., Broad R; Adaptimmune Limited, Abingdon, United Kingdom., Batrakou DG; Adaptimmune LLC, Philadelphia, PA, United States., Wang R; Adaptimmune Limited, Abingdon, United Kingdom., Solis LM; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Duose DY; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Sanderson JP; Adaptimmune Limited, Abingdon, United Kingdom., Gerry AB; Adaptimmune Limited, Abingdon, United Kingdom., Marks D; Adaptimmune LLC, Philadelphia, PA, United States., Bai J; Adaptimmune LLC, Philadelphia, PA, United States., Norry E; Adaptimmune LLC, Philadelphia, PA, United States., Fracasso PM; Adaptimmune LLC, Philadelphia, PA, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2022 Mar 18; Vol. 12, pp. 818679. Date of Electronic Publication: 2022 Mar 18 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2022.818679 |
